IRIS
VERGARO, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 24.774
AS - Asia 13.602
EU - Europa 12.136
SA - Sud America 3.220
Continente sconosciuto - Info sul continente non disponibili 354
AF - Africa 348
OC - Oceania 29
Totale 54.463
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 23.588
SG - Singapore 4.750
IT - Italia 3.705
CN - Cina 3.323
RU - Federazione Russa 3.210
BR - Brasile 2.513
VN - Vietnam 1.944
GB - Regno Unito 1.419
BD - Bangladesh 1.051
HK - Hong Kong 939
DE - Germania 835
CA - Canada 777
FR - Francia 507
UA - Ucraina 472
SE - Svezia 385
FI - Finlandia 340
IN - India 332
IE - Irlanda 269
AR - Argentina 251
MX - Messico 250
NL - Olanda 207
TR - Turchia 189
PL - Polonia 183
ID - Indonesia 171
IQ - Iraq 137
ES - Italia 134
ZA - Sudafrica 128
EC - Ecuador 127
DK - Danimarca 123
IL - Israele 119
JP - Giappone 118
PK - Pakistan 101
CO - Colombia 88
AT - Austria 85
VE - Venezuela 64
UZ - Uzbekistan 61
MA - Marocco 58
AE - Emirati Arabi Uniti 55
LT - Lituania 48
PY - Paraguay 47
CL - Cile 45
PE - Perù 36
SA - Arabia Saudita 36
PH - Filippine 35
EG - Egitto 32
MY - Malesia 32
CR - Costa Rica 29
KE - Kenya 29
TN - Tunisia 29
CH - Svizzera 27
UY - Uruguay 23
AZ - Azerbaigian 22
DZ - Algeria 22
EU - Europa 21
NP - Nepal 21
BE - Belgio 20
BO - Bolivia 20
JO - Giordania 20
AU - Australia 18
HN - Honduras 18
JM - Giamaica 17
DO - Repubblica Dominicana 15
GT - Guatemala 15
RO - Romania 15
AL - Albania 14
KZ - Kazakistan 14
CZ - Repubblica Ceca 13
OM - Oman 13
TH - Thailandia 13
TW - Taiwan 12
NI - Nicaragua 11
SK - Slovacchia (Repubblica Slovacca) 11
AM - Armenia 10
GR - Grecia 10
HU - Ungheria 10
IR - Iran 10
PA - Panama 10
PT - Portogallo 9
BB - Barbados 8
BY - Bielorussia 8
KR - Corea 8
KW - Kuwait 8
LB - Libano 8
MC - Monaco 8
NZ - Nuova Zelanda 8
PS - Palestinian Territory 8
TT - Trinidad e Tobago 8
BG - Bulgaria 7
MD - Moldavia 7
PR - Porto Rico 7
SN - Senegal 7
BH - Bahrain 6
CG - Congo 6
ET - Etiopia 6
GE - Georgia 6
HR - Croazia 6
LV - Lettonia 6
MK - Macedonia 6
QA - Qatar 6
RS - Serbia 6
Totale 54.014
Salva come PNG Salva come JPEG
Città #
Dallas 4.562
Singapore 2.491
Ashburn 1.630
San Jose 1.566
Chicago 1.316
Beijing 1.275
Los Angeles 1.110
Hong Kong 881
Council Bluffs 657
Ho Chi Minh City 620
Moscow 590
Salt Lake City 555
Milan 543
Southend 540
New York 517
Buffalo 456
Chandler 453
Fairfield 416
Hanoi 383
Houston 349
Rome 336
Woodbridge 334
San Mateo 332
Santa Clara 314
Tampa 314
Wilmington 289
The Dalles 283
Seattle 281
São Paulo 266
Dublin 259
Elk Grove Village 249
Ann Arbor 243
Cambridge 242
Falls Church 232
Lauterbourg 231
Hefei 222
Boardman 218
Helsinki 209
Ottawa 198
Jacksonville 192
Dearborn 162
Pisa 161
Beauharnois 156
Portsmouth 155
Warsaw 155
Orem 151
Montreal 150
Munich 145
Stevenage 142
Phoenix 134
Florence 128
Sterling 123
Mexico City 122
Brooklyn 121
Frankfurt am Main 119
Dong Ket 117
Lancaster 116
London 115
Lawrence 107
Tel Aviv 106
Denver 100
Tokyo 100
Toronto 98
Miami 97
Poplar 95
Atlanta 94
Amsterdam 93
Istanbul 92
Chennai 87
Rio de Janeiro 87
Johannesburg 86
Stockholm 82
Da Nang 78
Naples 78
Nuremberg 77
Columbus 75
Dulles 72
Bologna 70
Turin 67
Detroit 60
Haiphong 60
Figino 58
Belo Horizonte 57
Manchester 57
Tashkent 56
San Diego 55
Boston 53
Lappeenranta 53
Washington 53
Genoa 52
Kansas City 51
Turku 51
Palermo 50
San Francisco 47
Brasília 46
Baghdad 44
Bari 44
Biên Hòa 44
Quito 44
Charlotte 43
Totale 31.545
Salva come PNG Salva come JPEG
Nome #
Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study 1.851
N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis 1.707
Cardiac remodelling - Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology 1.585
High prevalence of wild-type transthyretin cardiac amyloidosis in older adults with carpal tunnel syndrome, heart failure or increased left ventricular mass: The CAPTURE study 738
Valutazione delle caratteristiche analitiche e dei risultati clinici di un metodo in chemiluminescenza a cattura di microparticelle (CMIA) per il dosaggio della Galectina-3 sulla piattaforma ARCHITECT 700
Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY study 625
Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis 451
[18F]-Florbetaben PET/CT for Differential Diagnosis Among Cardiac Immunoglobulin Light Chain, Transthyretin Amyloidosis, and Mimicking Conditions 420
A simple echocardiographic score to rule out cardiac amyloidosis 394
Trastuzumab cardiotoxicity and drug cardioprotection in healthy and cardiac dysfunction mouse models 384
The heart failure specialists of tomorrow: a network for young cardiovascular scientists and clinicians 374
A simple echocardiographic score to rule out cardiac amyloidosis 371
Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging 337
Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers 334
Markers of fibrosis, inflammation, and remodeling pathways in heart failure 332
Arrhythmic risk prediction in non-dilated left ventricular cardiomyopathy: The role of overlap with arrhythmogenic cardiomyopathy 324
Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches 319
Adrenergic activation in heart failure: blockade or rebalance? 316
[18F]-florbetaben PET/CT is sensitive for cardiac AL amyloidosis 316
Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation 312
Amyloid deposits and fibrosis on left ventricular endomyocardial biopsy correlate with extracellular volume in cardiac amyloidosis 311
Clinical and prognostic significance of central and obstructive apnoeas in patients with transthyretin cardiac amyloidosis 308
Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy 308
Eligibility for vericiguat in a real‐world, contemporary heart failure population 307
Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis 306
Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis 304
CHADS2 and CHA2DS2-VASc scores to predict morbidity and mortality in heart failure patients candidates to cardiac resynchronization therapy 303
Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure 301
A mechanistic look at sacubitril/valsartan action. Unravelling magician's secrets 300
[Ten perspectives for research and innovation in cardiac amyloidosis] 299
[Rationale and significance of the Italian Network for Cardiac Amyloidosis] 297
Screening the health status of people working in a university 296
A prognostically meaningful definition of non-dilated left ventricular cardiomyopathy 292
Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure 289
How to take arms against central apneas in heart failure 289
Cheyne-Stokes respiration related oscillations in cardiopulmonary hemodynamics in patients with heart failure 285
Sex-related differences in chronic heart failure 284
Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction 281
A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization - the first insight from the AC-TIVE Study 278
NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure 278
Approach to the diagnosis and management of patients with cardiac amyloidosis. A consensus document by the Tuscan section of the Italian Association of Hospital Cardiologists (ANMCO) and the Tusco-Umbrian section of the Italian Society of Cardiology (SIC) 278
Central And Obstructive Apneas in Heart Failure With Reduced, Mid-Range And Preserved Ejection Fraction. 276
Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure 276
RNA-targeting and gene editing therapies for transthyretin amyloidosis 275
Cardiac light-chain deposition disease relapsing in the transplanted heart 274
Prognostic significance of myocardial extracellular volume fraction in nonischaemic dilated cardiomyopathy 273
Clinical relevance of non-cardiac determinants of natriuretic peptide levels. 270
Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study 268
Atrial amyloidosis: mechanisms and clinical manifestations 268
Contribution of the lung to the genesis of cheyne-stokes respiration in heart failure: Plant gain beyond chemoreflex gain and circulation time 268
Cardiac magnetic resonance findings and prognosis in type 1 myotonic dystrophy 267
Refractory hyperaldosteronism in heart failure is associated with plasma renin activity and angiotensinogen polymorphism 266
Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice 266
Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure 265
Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible? 264
Are big data on myocardial infarction enough for small heart failure patients? Lessons from a national registry 264
Update sui biomarcatori nello scompenso cardiaco. 262
Valve disease in cardiac amyloidosis: an echocardiographic score 261
Biomarkers for the diagnosis and management of heart failure: New frontiers 260
null 258
Disease features and management of cardiomyopathies in women 258
null 253
Biomarkers for the diagnosis and management of heart failure 253
Biomarkers for the diagnosis and management of heart failure: Natriuretic peptides 251
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology 247
In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation 247
The search for efficient diagnostic and prognostic biomarkers of heart failure 245
Discharge FGF23 level predicts one year outcome in patients admitted with acute heart failure 245
Renin profiling predicts neurohormonal response to sacubitril/valsartan 244
Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis 242
Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction 242
Role of Imaging in Cardiomyopathies 241
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 241
Breathing Not Properly in the oldest old. Is brain natriuretic peptide a poor test for the diagnosis of heart failure in the elderly? 241
Valvular heart disease in patients with cardiac amyloidosis 240
Percorsi diagnostico-terapeutici assistenziali per i pazienti con amiloidosi cardiaca – Documento di consenso SIC/ANMCO. A cura della Rete Italiana dell’Amiloidosi Cardiaca (RIAC) 238
[Diagnostic-therapeutic care pathways for patients with cardiac amyloidosis - SIC/ANMCO Consensus document. Edited by the Italian Cardiac Amyloidosis Network (RIAC)] 238
Predicting readmissions after hospitalization for heart failure: Medical reasoning vs calculators 238
Cardiac amyloidosis characterization by kinetic model fitting on [18F]florbetaben PET images 237
Correction of procedural arterial pseudoaneurysms: Established and novel procedures 235
Early diagnosis, disease stage and prognosis in wild‐type transthyretin amyloid cardiomyopathy: The DIAMOND study 234
Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND study 232
The IL-33/ST2 pathway, inflammation and atherosclerosis: Trigger and target? 230
Current and emerging treatment options for transthyretin amyloid cardiomyopathy 229
Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies 228
null 228
Prognostic value of plasma Renin activity in heart failure. 227
Sacubitril–valsartan treatment is associated with decrease in central apneas in patients with heart failure with reduced ejection fraction 227
Abdominal Fat Biopsy for the Diagnosis of Cardiac Amyloidosis 227
Etiological Treatment of Cardiac Amyloidosis: Standard of Care and Future Directions 226
Effects of sacubitril-valsartan on remodelling, fibrosis and mitochondria in a murine model of isoproterenol-induced left ventricular dysfunction 226
null 226
Deep learning to diagnose cardiac amyloidosis from cardiovascular magnetic resonance 226
Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient 224
Cardiac amyloidosis: Innovations in diagnosis and treatment 223
Beta-blocking patients with cardiac amyloidosis: Adelante cum juicio 223
Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings 223
Central Apneas Are More Detrimental in Female Than in Male Patients With Heart Failure 222
The Role of Scintigraphy with Bone Radiotracers in Cardiac Amyloidosis 222
Deep-learning-based cardiac amyloidosis classification from early acquired pet images 221
Totale 32.865
Salva come PNG Salva come JPEG
Categoria #
all - tutte 256.641
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 256.641
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.773 0 299 80 198 75 69 202 338 142 199 36 135
2022/20231.348 110 112 62 143 166 178 36 120 253 30 83 55
2023/20241.338 76 36 239 102 73 120 105 65 51 75 55 341
2024/202513.829 112 134 492 202 421 496 1.194 2.132 818 2.025 3.144 2.659
2025/202629.663 1.484 4.089 3.967 3.856 2.799 1.809 2.701 1.353 1.812 1.914 2.033 1.846
2026/20271.594 777 817 0 0 0 0 0 0 0 0 0 0
Totale 54.463